Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC.

Brain. 2018 Nov 1;141(11):3233-3248. doi: 10.1093/brain/awy244.

PMID:
30304397
2.

Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers.

Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM.

Alzheimers Dement. 2018 May;14(5):610-616. doi: 10.1016/j.jalz.2017.11.011. Epub 2018 Jan 10.

3.

Preclinical Alzheimer's disease and longitudinal driving decline.

Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC.

Alzheimers Dement (N Y). 2017 Jan;3(1):74-82. doi: 10.1016/j.trci.2016.11.006.

4.

Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.

Day GS, Lim TS, Hassenstab J, Goate AM, Grant EA, Roe CM, Cairns NJ, Morris JC.

Neurology. 2017 Mar 28;88(13):1273-1281. doi: 10.1212/WNL.0000000000003770. Epub 2017 Feb 24.

5.

Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.

Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Ott BR, Holtzman DM, Benzinger TL, Fagan AM, Carr DB, Morris JC.

Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):69-72. doi: 10.1097/WAD.0000000000000154.

6.

Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.

Ingber AP, Hassenstab J, Fagan AM, Benzinger TL, Grant EA, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2016;52(3):1055-64. doi: 10.3233/JAD-150478.

7.

CSF biomarkers of Alzheimer disease: "noncognitive" outcomes.

Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC.

Neurology. 2013 Dec 3;81(23):2028-31. doi: 10.1212/01.wnl.0000436940.78152.05. Epub 2013 Nov 8.

8.

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM.

Lancet Neurol. 2013 Oct;12(10):957-65. doi: 10.1016/S1474-4422(13)70194-7. Epub 2013 Sep 4.

9.

Preclinical Alzheimer disease and risk of falls.

Stark SL, Roe CM, Grant EA, Hollingsworth H, Benzinger TL, Fagan AM, Buckles VD, Morris JC.

Neurology. 2013 Jul 30;81(5):437-43. doi: 10.1212/WNL.0b013e31829d8599. Epub 2013 Jun 26.

10.

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.

Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TL, Mintun MA, Holtzman DM, Morris JC.

Neurology. 2013 May 7;80(19):1784-91. doi: 10.1212/WNL.0b013e3182918ca6. Epub 2013 Apr 10.

11.

An examination of the integration of certified peer specialists into community mental health centers.

Grant EA, Reinhart C, Wituk S, Meissen G.

Community Ment Health J. 2012 Aug;48(4):477-81. doi: 10.1007/s10597-012-9519-9. Epub 2012 Jul 18.

PMID:
22806435
12.

Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.

Roe CM, Fagan AM, Grant EA, Marcus DS, Benzinger TL, Mintun MA, Holtzman DM, Morris JC.

Arch Neurol. 2011 Sep;68(9):1145-51. doi: 10.1001/archneurol.2011.192.

13.

Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease.

Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC.

Neurology. 2011 Feb 8;76(6):501-10. doi: 10.1212/WNL.0b013e31820af900. Epub 2011 Jan 12.

14.

Alzheimer disease identification using amyloid imaging and reserve variables: proof of concept.

Roe CM, Mintun MA, Ghoshal N, Williams MM, Grant EA, Marcus DS, Morris JC.

Neurology. 2010 Jul 6;75(1):42-8. doi: 10.1212/WNL.0b013e3181e620f4.

15.

Driving Retirement in Older Adults with Dementia.

Croston J, Meuser TM, Berg-Weger M, Grant EA, Carr DB.

Top Geriatr Rehabil. 2009 Apr 1;25(2):154-162.

16.

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA.

Arch Neurol. 2009 Dec;66(12):1469-75. doi: 10.1001/archneurol.2009.269.

17.

Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness.

Avidan MS, Searleman AC, Storandt M, Barnett K, Vannucci A, Saager L, Xiong C, Grant EA, Kaiser D, Morris JC, Evers AS.

Anesthesiology. 2009 Nov;111(5):964-70. doi: 10.1097/ALN.0b013e3181bc9719.

18.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

19.

Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake.

Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC.

Arch Neurol. 2008 Nov;65(11):1467-71. doi: 10.1001/archneur.65.11.1467.

20.

Combined retinal hamartomas leading to the diagnosis of neurofibromatosis type 2.

Grant EA, Trzupek KM, Reiss J, Crow K, Messiaen L, Weleber RG.

Ophthalmic Genet. 2008 Sep;29(3):133-8. doi: 10.1080/13816810802206507.

PMID:
18766994
21.

Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI.

Storandt M, Grant EA, Miller JP, Morris JC.

Neurology. 2006 Aug 8;67(3):467-73.

PMID:
16894109
22.

The neuropathology of Alzheimer disease in African American and white individuals.

Wilkins CH, Grant EA, Schmitt SE, McKeel DW, Morris JC.

Arch Neurol. 2006 Jan;63(1):87-90.

PMID:
16401740
23.

Brief screening tests for the diagnosis of dementia: comparison with the mini-mental state exam.

Kilada S, Gamaldo A, Grant EA, Moghekar A, Morris JC, O'Brien RJ.

Alzheimer Dis Assoc Disord. 2005 Jan-Mar;19(1):8-16.

PMID:
15764865
24.

Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type.

McKeel DW Jr, Price JL, Miller JP, Grant EA, Xiong C, Berg L, Morris JC.

J Neuropathol Exp Neurol. 2004 Oct;63(10):1028-37.

PMID:
15535130
25.

Absence of effect of depression on cognitive performance in early-stage Alzheimer disease.

Powlishta KK, Storandt M, Mandernach TA, Hogan E, Grant EA, Morris JC.

Arch Neurol. 2004 Aug;61(8):1265-8.

PMID:
15313845
26.

Analysis of the antitumoral mechanisms of lipopolysaccharide against glioblastoma multiforme.

Won EK, Zahner MC, Grant EA, Gore P, Chicoine MR.

Anticancer Drugs. 2003 Jul;14(6):457-66.

PMID:
12853889
27.

Accuracy of collateral source reports in very mild to mild dementia of the Alzheimer type.

Cacchione PZ, Powlishta KK, Grant EA, Buckles VD, Morris JC.

J Am Geriatr Soc. 2003 Jun;51(6):819-23.

PMID:
12757569
28.

Rates of progression in mild cognitive impairment and early Alzheimer's disease.

Storandt M, Grant EA, Miller JP, Morris JC.

Neurology. 2002 Oct 8;59(7):1034-41.

PMID:
12370458
29.

Absence of cognitive impairment or decline in preclinical Alzheimer's disease.

Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW Jr, Rubin EH, Morris JC.

Neurology. 2001 Feb 13;56(3):361-7.

PMID:
11171902
30.
31.

A prospective study of cognitive function and onset of dementia in cognitively healthy elders.

Rubin EH, Storandt M, Miller JP, Kinscherf DA, Grant EA, Morris JC, Berg L.

Arch Neurol. 1998 Mar;55(3):395-401.

PMID:
9520014
32.

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease.

Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, Berg L.

Neurology. 1996 Mar;46(3):707-19.

PMID:
8618671
33.

Randomized trial to determine the optimum level of pouch-anal anastomosis in stapled restorative proctocolectomy.

Deen KI, Williams JG, Grant EA, Billingham C, Keighley MR.

Dis Colon Rectum. 1995 Feb;38(2):133-8.

PMID:
7851166
34.

Randomized trial of internal anal sphincter plication with pelvic floor repair for neuropathic fecal incontinence.

Deen KI, Kumar D, Williams JG, Grant EA, Keighley MR.

Dis Colon Rectum. 1995 Jan;38(1):14-8.

PMID:
7813338
35.

Scintigraphic defecography: quantitative and dynamic assessment of anorectal function.

Hutchinson R, Mostafa AB, Grant EA, Smith NB, Deen KI, Harding LK, Kumar D.

Dis Colon Rectum. 1993 Dec;36(12):1132-8.

PMID:
8253010
36.

Gadolinium enhancement in acute and chronic-progressive experimental allergic encephalomyelitis in the guinea pig.

Karlik SJ, Grant EA, Lee D, Noseworthy JH.

Magn Reson Med. 1993 Sep;30(3):326-31.

PMID:
8412603
37.

Influence of age on clinical and psychometric assessment of subjects with very mild or mild dementia of the Alzheimer type.

Rubin EH, Storandt M, Miller JP, Grant EA, Kinscherf DA, Morris JC, Berg L.

Arch Neurol. 1993 Apr;50(4):380-3.

PMID:
8460959
38.

The influence of major depression on clinical and psychometric assessment of senile dementia of the Alzheimer type.

Rubin EH, Kinscherf DA, Grant EA, Storandt M.

Am J Psychiatry. 1991 Sep;148(9):1164-71.

PMID:
1882993
39.

Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging.

Morris JC, McKeel DW Jr, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L.

Neurology. 1991 Apr;41(4):469-78.

PMID:
2011242
40.

Senile dementia and healthy aging: a longitudinal CT study.

Wippold FJ 2nd, Gado MH, Morris JC, Duchek JM, Grant EA.

Radiology. 1991 Apr;179(1):215-9.

PMID:
2006279
41.

Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors?

Morris JC, Drazner M, Fulling K, Grant EA, Goldring J.

Arch Neurol. 1989 Jun;46(6):651-7.

PMID:
2730377
42.

Very mild senile dementia of the Alzheimer type. I. Clinical assessment.

Rubin EH, Morris JC, Grant EA, Vendegna T.

Arch Neurol. 1989 Apr;46(4):379-82.

PMID:
2650663
43.

Evaluating risk transactions.

Grant EA.

Trustee. 1988 Apr;41(4):19. No abstract available.

PMID:
10302361
44.

Evaluating mergers and acquisitions with a purchase investigation.

Grant EA, Giniat EJ.

Healthc Financ Manage. 1988 Apr;42(4):72-3, 76-8, 80-2.

PMID:
10286386
45.

Mergers and acquisitions: new arrangements in health care. Part 1.

Grant EA.

Healthc Financ Manage. 1988 Feb;42(2):25-8, 30-2, 34-6.

PMID:
10285688
46.

Upgrading financial planning and reporting in response to DRG requirements.

Monroe RD, Grant EA.

Top Health Care Financ. 1985 Spring;11(3):63-71. No abstract available.

PMID:
3920788
47.

Remote memory as a function of age and sex.

Storandt M, Grant EA, Gordon BC.

Exp Aging Res. 1978 Oct;4(5):365-75.

PMID:
738316
48.

Incentive and practice in the psychomotor performance of the elderly.

Grant EA, Storandt M, Botwinick J.

J Gerontol. 1978 May;33(3):413-5.

PMID:
748435
49.

Inhibition by atropine, phenoxybenzamine and propranolol of the autonomic nervous system of the domestic fowl.

Szeto PM, Grant EA, Lioy F, Parkes CO.

Poult Sci. 1977 Jul;56(4):1201-5.

PMID:
605077

Supplemental Content

Loading ...
Support Center